Early detection of lung adenocarcinoma (LUAD) remains a major clinical challenge despite the widespread application of low-dose computed tomography (LDCT). Circulating PIWI-interacting RNAs (piRNAs), characterized by tumor-specific expression and hig...
BACKGROUND: Lung adenocarcinoma (LUAC) patients with micropapillary (MP) and/or solid (S) generally demonstrate a poorer survival prognosis. In the diagnosis and treatment of stage IA LUAC, precisely establishing personalized treatment strategies for...
Although it is the most common subtype of lung cancer in clinical practice, lung adenocarcinoma (LUAD) was proven to be associated with a poor prognosis. In recent years, lactate metabolism has been considered an important biological mechanism in lun...
Mitochondrial autophagy (mitophagy) in macrophages is crucial yet poorly understood within the lung adenocarcinoma (LUAD) tumor microenvironment. This study aimed to identify key macrophage mitophagy-related genes and develop a robust prognostic mode...
This study aimed to investigate the relationship between methylation quantitative trait loci (meQTL) and lung adenocarcinoma (LUAD) susceptibility. Candidate SNPs linked to differentially methylated CpG sites in LUAD were identified through meQTL dat...
Journal of cancer research and clinical oncology
Nov 8, 2025
AIM: Vasculogenic mimicry (VM), a process in which cancer cells form endothelial cell-independent vascular networks, is a hallmark of tumor aggressiveness in lung adenocarcinoma (LUAD) and supports tumor growth and metastasis. This study aims to iden...
Lung adenocarcinoma (LUAD) is a highly aggressive lung cancer with poor prognosis due to lack of reliable biomarkers. Resistance to anoikis drives tumor progression and metastasis. This study aims to develop and validate an anoikis-related prognostic...
BACKGROUND: Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has high incidence and poor prognosis. Although anti-programmed cell death protein 1 (PD1) therapy and epidermal growth factor receptor (EGFR) inhibitors benefit...
The tumor microenvironment (TME) is associated with tumor prognosis, immunotherapy response, and prognosis in patients. Here, we hypothesized that the entire TME in pathology image is associated with the survival time prediction. To address this hypo...
BACKGROUND: Immunogenic cell death (ICD) triggers antitumor immune responses and plays a critical role in shaping the tumor microenvironment (TME). However, its specific contribution to lung adenocarcinoma (LUAD) progression and immunotherapy respons...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.